3rd Annual Perspectives in Genitourinary Oncology: A Case-based Approach to Enhance Patient Management of Prostate, Renal and Bladder Cancer

11. 9. 2009 - 12. 9. 2009, Westin Michigan Avenue, Chicago, Illinois, USA

Registrace

Friday, September 11, 2009
8:00 am Welcome and introduction Mark S. Soloway, MD
Session I: Prostate Cancer Moderator: Mark S. Soloway, MD
8:05 am Alternative treatments for low risk prostate cancer including active surveillance Laurence Klotz, MD
8:25 am Role of radiation therapy for clinically localized prostate cancer Alan Pollack, MD, PhD
8:45 am Questions
8:55 am Expert Discussion Moderator: Mark S. Soloway, MD
Panel: Dean F. Bajorin, MD, Robert Dreicer, MD, FACP, Laurence Klotz, MD, and Alan Pollack, MD, PhD
Cases:
#1: Low risk patient
#2: Locally advanced patient
#3: PSA failure patient post surgery
#4: Rising PSA following radiation therapy
#5: Consideration for prostate cancer prevention
10:00 am Coffee break
Break Out Discussions in Prostate Cancer
Discussion 1: Management of low & intermediate risk prostate cancer
10:20 am Expert Case Discussion Moderator: Mark S. Soloway, MD
Panel: Steven C. Campbell, MD, PhD, Laurence Klotz, MD, Arthur I. Sagalowsky, MD, and Alan Pollack, MD, PhD
Cases:
#1: Technical aspects of patient to have prostatectomy for cT1 – 2 prostate cancer
#2: Elevated PSA and negative prostate biopsy. Role of additional biopsies, MRI, other markers,etc
#3: Salvage therapy for patient after radiation and now rising PSA
#4: Role of HIFU and cryotherapy for low risk prostate cancer
Discussion 2: Management of advanced prostate cancer
10:20 am Managing PSA failure patients referred from urology Robert Dreicer, MD, FACP
10:40 am Expert Case Discussion Moderator: Robert Dreicer, MD, FACP
Panel: Dean F. Bajorin, MD and Brian I. Rini, MD
Cases:
#1: PSA progression in the castrate setting, no evidence of metastases I ssues: when to image, role of PSA kinetics, role/rational of second line hormonal therapy and potential new agents i.e. abiraterone
#2: Patient with asymptomatic castrate progressive disease I ssues: When to start docetaxel, how long to treat, bisphosphonate use
# 3: Patient with moderate symptoms post docetaxel: role of salvage therapy, second line hormonal agents, retreatment with docetaxel other agents, investigational options
12:00 pm Lunch break: Meet the professor
Session II: Bladder Cancer Moderator: Mark S. Soloway, MD
1:00 pm Management of locally advanced bladder cancer Dean F. Bajorin, MD
1:20 pm Novel emerging therapies for bladder cancer Robert Dreicer, MD, FACP
1:40 pm Questions
1:50 pm Expert Case Discussion Moderator: Mark S. Soloway, MD
Panel: Dean F. Bajorin, MD, Steven C. Campbell, MD, PhD, Robert Dreicer, MD, FACP, and Arthur I. Sagalowsky, MD
Cases:
#1: BCG failure patient
#2: Locally advanced patient with obvious pelvic nodal disease
#3: High grade T2 with a lymphovascular invasion
#4: Small cell bladder cancer
3:00 pm Coffee break
Break Out Discussions in Bladder Cancer
Discussion 1: Management of low & moderate risk bladder cancer
3:20 pm Expert Discussion Moderator: Mark S. Soloway, MD
Panel: Steven C. Campbell, MD, PhD, Arthur I. Sagalowsky, MD,and Gary Steinberg, MD
Cases:
#1: Recurrent low grade Ta after TUR BT
#2: Recurrent HG T1 TCC after BCG
#3: TCC of the upper urinary tract, low grade biopsy
#4: Adenocarcinoma of the bladder
Discussion 2: Management of advanced bladder cancer
3:20 pm Expert Discussion Moderator: Robert Dreicer, MD, FACP
Panel: Dean F. Bajorin, MD
Cases:
#1: Locally advanced patient with renal compromise
I ssue: Decision making regarding therapy in unfit patients
#2: Renal pelvis TCC with regional nodes, role time of surgery and chemotherapy
#3: Advanced disease patient progressed after front-line chemotherapy Issue: How to select optimal salvage therapy
4:30 pm Adjourn
Saturday, September 12, 2009
8:00 am Welcome and introduction Robert Dreicer, MD, FACP
Session II: Renal Cancer Moderator: Robert Dreicer, MD, FACP
8:05 am Management of small renal masses Steven C. Campbell, MD, PhD
8:25 am Therapeutic management of locally advanced renal cancer Brian I. Rini, MD
8:45 am Questions
8:55 am Expert Discussion Moderator: Mark S. Soloway, MD
Panel: Steven C. Campbell, MD, PhD, Robert Dreicer, MD, FACP, Brian I. Rini, MD, and Walter M. Stadler, MD
Cases:
#1: Small renal lesions
#2: Locally advanced clear cell carcinoma
#3: Patient with minimal metastatic disease
#4: Patient with resected T2B with and without positive lymph nodes
10:00 am Coffee break
Break Out Discussions in Renal Cancer
Discussion 1: Management of low & moderate risk renal cancer
10:20 am Expert Discussion Moderator: Mark S. Soloway, MD
Panel: Steven C. Campbell, MD, PhD
Cases:
#1: Technical aspects of renal cell carcinoma with involvement of the vena cava
#2: Open versus laparoscopic partial nephrectomy
#3: Bilateral renal tumors
#4: Complex cyst - role of biopsy
Discussion 2: Management of advanced renal cancer
10:20 am Current status of front line therapy for management of advanced renal cancer patients Brian I. Rini, MD
10:40 am Expert Discussion Moderator: Robert Dreicer, MD, FACP
Panel: Brian I. Rini, MD and Walter M. Stadler, MD
Cases:
#1: Metastatic clear cell patient, disease progression on front line TKI I ssues: role/rationale data for second line therapy, dosing issues of TKI, role of mTOR in second line
#2: Metastatic clear cell patient develops toxicity with TKI managing toxicity of TKI, dose, dose escalation issues
#3: Patient with metastatic clear cell renal cancer, response to bevacizumab/interferon Issue: Integrating surgery following response in the metastatic setting
12:00 pm Lunch break
Session IV: Highlights from 2008 Meetings Moderator: Robert Dreicer, MD, FACP
1:00 pm Highlights from AUA Steven C. Campbell, MD, PhD
1:30 pm Highlights from ASCO Walter M. Stadler, MD
2:00 pm Questions
2:10 pm Coffee break
Session V: Testis Cancer Moderator: Mark S. Soloway, MD
2:30 pm State of the art on testis tumor from urologist perspective Arthur I. Sagalowsky, MD
2:50 pm Expert Discussion Moderator: Mark S. Soloway, MD
Panel: Robert Dreicer, MD, FACP and Arthur I. Sagalowsky, MD
Cases:
#1: II C seminoma, managing the residual mass
#2: Growing teratoma s/p chemotherapy for intermediate risk NSGCT
#3: Missed node in landing zone growing over the years
#4: NCGCT managing opposite testes with microcalcifications
4:00 pm Adjourn

Kontakt: meetings@imedex.com

Web: http://www.imedex....ements/a103-01.asp

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live